45 results on '"van der Meijden, Edith D."'
Search Results
2. Chaperone protein HSC70 regulates intercellular transfer of Y chromosome antigen DBY
3. Supplementary Figure 1 from T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells
4. Supplementary Figure 2 from T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells
5. Data from T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells
6. Supplemental Methods, Supplementary Figures 1-4, Supplementary Table 1 from Integrated Whole Genome and Transcriptome Analysis Identified a Therapeutic Minor Histocompatibility Antigen in a Splice Variant of ITGB2
7. Supplementary Tables 1-3 from High-Throughput Characterization of 10 New Minor Histocompatibility Antigens by Whole Genome Association Scanning
8. Data from High-Throughput Characterization of 10 New Minor Histocompatibility Antigens by Whole Genome Association Scanning
9. Supplementary Figure 1 from High-Throughput Characterization of 10 New Minor Histocompatibility Antigens by Whole Genome Association Scanning
10. Human Leukocyte Antigen–DO Regulates Surface Presentation of Human Leukocyte Antigen Class II–Restricted Antigens on B Cell Malignancies
11. Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO
12. Identification of Phosphatidylinositol 4-Kinase Type II β as HLA Class II-Restricted Target in Graft versus Leukemia Reactivity
13. HLA-DPB1 Mismatching Results in the Generation of a Full Repertoire of HLA-DPB1-Specific CD4 + T Cell Responses Showing Immunogenicity of all HLA-DPB1 Alleles
14. Influence of DM-sensitivity on immunogenicity of MHC class II restricted antigens
15. Identification of 4 new HLA-DR–restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity
16. Human CD4+ T cells specific for dominant epitopes of SARS-CoV-2 Spike and Nucleocapsid proteins with therapeutic potential
17. Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy
18. Identification of phosphatidylinositol 4-kinase type II [beta] as HLA class II-restricted target in graft versus leukemia reactivity
19. Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility Antigens
20. Natural T-cell ligands that are created by genetic variants can be transferred between cells by extracellular vesicles
21. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer
22. Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility Antigens
23. Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing
24. Successful treatment of COVID‐19 infection with convalescent plasma in B‐cell‐depleted patients may promote cellular immunity.
25. Human CD4+ T cells specific for dominant epitopes of SARS‐CoV‐2 Spike and Nucleocapsid proteins with therapeutic potential.
26. T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells
27. Whole Transcriptome RNA Sequencing As a Comprehensive Diagnostic Tool for Acute Myeloid Leukemia
28. Whole Transcriptome Sequencing (RNAseq) As a Comprehensive, Cost-Efficient Diagnostic Tool for Acute Myeloid Leukemia
29. Integrated Whole Genome and Transcriptome Analysis Identified a Therapeutic Minor Histocompatibility Antigen in a Splice Variant of ITGB2
30. Both permissive and nonpermissive HLA-DPB1 mismatches can induce polyclonal HLA-DPB1 specific immune responses in vivo and in vitro
31. High Throughput Screening for Antibody Responses Against H-Y Antigens and Their X-Variants in Allogeneic Hematopoeietic Stem Cell Transplantation,
32. Primary Antibody Responses Against the Novel Pandemic H1N1 and Secondary Antibody Responses Against Seasonal H1N1 Can Be Induced by Vaccination In Patients Early After Allogeneic Stem Cell Transplantation
33. High-Throughput Characterization of 10 New Minor Histocompatibility Antigens by Whole Genome Association Scanning
34. HLA-DPB1 Mismatching Results in the Generation of a Full Repertoire of HLA-DPB1-Specific CD4+ T Cell Responses Showing Immunogenicity of all HLA-DPB1 Alleles
35. High Throughput Minor Histocompatibility Antigen Discovery by Whole Genome Association Scanning.
36. Diversity of HLA Class I and Class II Restricted Minor Histocompatibility Antigens in Graft-Versus-Leukemia Reactivity.
37. Identification of Four New HLA Class II Restricted Minor Histocompatibility Antigens Contributing to Graft Versus Leukemia Reactivity.
38. HLA-DPB1 Mismatching Results in the Generation of a Full Repertoire of HLA-DPB1 Specific T Cell Responses Showing Immunogenicity of All HLA-DPB1 Alleles
39. Detailed Analysis of CD8+ T Cell Immunity and Identification of a Novel Minor Histocompatibility Antigen Contributing to Graft-Versus- Leukemia Reactivity.
40. Identification of Phosphatidylinositol 4-Kinase Type II β as the First HLA Class II Associated Minor Histocompatibility Antigen Involved in Graft Versus Leukemia Reactivity.
41. Identification of the Angiogenic Endothelial Cell Growth Factor-1/Thymidine Phosphorylase as a Target for Immunotherapy of Cancer.
42. HLA-DPB1 Mismatching Results in the Generation of a Full Repertoire of HLA-DPB1-Specific CD4+ T Cell Responses Showing Immunogenicity of all HLA-DPB1 Alleles
43. Human CD4 + T cells specific for dominant epitopes of SARS-CoV-2 Spike and Nucleocapsid proteins with therapeutic potential.
44. Development of a coordinated allo T cell and auto B cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantation.
45. Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.